PROMPT
You are the CEO of a mid-sized, publicly-traded pharmaceutical company, St. Alan Inc. (SAI),
that has recently come out with a brand new over-the-counter (you can purchase without a
doctor’s prescription weight
...
PROMPT
You are the CEO of a mid-sized, publicly-traded pharmaceutical company, St. Alan Inc. (SAI),
that has recently come out with a brand new over-the-counter (you can purchase without a
doctor’s prescription weight-pill called RossLess (RL). The active ingredient is
Monsodohaasinate, a new stimulant that actually burns calories by increasing blood flow to
chemically convince the body that it is in a state of physical exertion.
Trials performed by the company proved that the product led to exceptional weight loss for
middle-aged men between the ages of 30 and 55. Obesity is a direct cause of heart disease,
diabetes, and many other diseases, and is associated with more than $300 billion in health care
costs each year in the US.
St. Alan Inc. took on a tremendous financial burden developing this drug, dedicating almost 75%
of its R&D budget to bring the rug to market following the rigorous tests demanded by the FDA.
(From a Friedman point of view, higher input costs for this drug would entail the absolute
necessity that it return on its production burdens; thus, although the product itself has
the potential to drop in profits, it must be sold either way, otherwise, the company
wouldn’t be maximizing its returns on investment.)
Considering the costs of developing this drug, many large investors have expressed concern
about St. Alan Inc’s profits, and this lack of investor confidence has led to a 10% drop in the
company’s stock price over the last two years. (A decrease in short term stocks signals that
investors, particularly shareholders, have low confidence in the financial performance of
the product, and thus in profits as well. Despite these concerns, the best thing SAI
leadership can do moving forward it to put the product on the market, regardless of its
effects on society; the only way to increase profits is to put it on the market.)
Three days before the drug debuts in stores around the country, your VP of Product Design, H.I.
McDonough (HIM) demands as an emergency meeting with the executive board. Present at the
meeting are you (the CEO), COO Max Bialistock (MB), and CFO Egbert Souse (ES).
H.I. McDonough: “I have horrible news. One week ago I was gettin greedy to go home to see
my family, I…. um… accidentally ground up RossLess into a powder and snorted it up my nose.
I found out it was a powerful hallucinogenic drug!”
H.I. McDonough discusses his findings, showing that in tests he’s conducted he found that the
addictive properties of RossLess are almost exactly as potent as cocaine. The long-term side
effects of the drug in this form are unclear, however, aside from the addiction there does not
appear to be any kind of permanent damage.
COO Max Bialistock: “This is a disaster. Most of the drug is already in shipment. We will take a
serious financial loss in the recall, but we cannot allow such a dangerous product to be sold. We
have to notify the public and recall the product.”
CIO EgbertSouse: “I say we keep this matter to ourselves and release RossLess as scheduled.
[Show More]